Eluminex exits stealth with $50m
The ophthalmic biotherapeutics developer has completed a series A round co-led by Eli Lilly unit Lilly Asia Ventures nine months after it was founded.
Well Health sells Summation on $45m round
Summation Health Ventures returned for a series C round that lifted the healthcare communication system provider's total funding to $45m.
Telus tells of impact fund
Telus Pollinator Fund for Good is equipped with $76.5m to invest in developers of technology that can promote positive social and environmental impact.
Subtle Medical sucks in series A funds
Baidu-backed Subtle Medical produces AI-driven medical imaging software intended to work across different healthcare systems, and has raised $12.2m.
Catamaran Bio catalyses $42m
Takeda Ventures and Astellas Venture Management both backed cell therapy developer Catamaran as it emerged from stealth.
Resilience reveals $800m at launch
GV is among the investors in the pharmaceutical manufacturing technology startup, which recently secured $750m in series B funding.
K Health carries out $42m series D
The Comcast and Anthem-backed telemedicine app developer closed its second round of the year, at a reported $700m valuation.
GV steers Headway to $26m series A
The Alphabet investment vehicle has helped the online therapist network close a series A round that increased its total funding to $32m.

Other News

Antengene accelerates to $360m flotation
The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.
Medable heads to $91m series C
Strategic partner PPD returned for a round that helped the clinical trial software provider take its total funding past the $130m mark.
Imago BioSciences impresses with $80m series C
Pharmaron Investments, Amgen Ventures and MRL Ventures Fund helped the bone marrow cancer drug developer double its total funding to about $160m.
Orange calls up LBO France fund
LBO France’s Digital Health 2, which has a targeted close of about $240m, has secured Orange and its Enovacom subsidiary as a limited partner.
Corporate venturing deal net: 16-20 November 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
SR One spins off with $500m
GlaxoSmithKline's corporate venturing unit is now an independent firm with a $500m fund anchored by its former parent.

Editor's Picks

SR One spins off with $500m
GlaxoSmithKline's corporate venturing unit is now an independent firm with a $500m fund anchored by its former parent.
Merck & Co marks $2.75bn VelosBio purchase
Takeda Ventures and Chiesi Ventures are set to exit the cancer drug developer through the deal, which came after just over $200m in funding.
Galecto gathers $85m in initial public offering
Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.
Aligos accesses public markets with $150m
Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.
test reg